RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 146 filers reported holding RECURSION PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is 0.32 and the average weighting 2.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,530,000 | -43.9% | 200,000 | -45.2% | 0.01% | -57.9% |
Q2 2023 | $2,726,550 | -2.7% | 365,000 | -13.1% | 0.02% | -29.6% |
Q1 2023 | $2,801,400 | -9.2% | 420,000 | +5.0% | 0.03% | -50.0% |
Q4 2022 | $3,084,000 | -3.4% | 400,000 | +33.3% | 0.05% | +50.0% |
Q3 2022 | $3,192,000 | +30.7% | 300,000 | 0.0% | 0.04% | +24.1% |
Q2 2022 | $2,442,000 | +13.7% | 300,000 | 0.0% | 0.03% | +11.5% |
Q1 2022 | $2,148,000 | -55.2% | 300,000 | +7.1% | 0.03% | -50.0% |
Q4 2021 | $4,796,000 | -21.4% | 280,000 | +5.7% | 0.05% | -16.1% |
Q3 2021 | $6,098,000 | -33.8% | 265,000 | +5.0% | 0.06% | -18.4% |
Q2 2021 | $9,216,000 | – | 252,500 | – | 0.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Obvious Management Services, L.L.C. | 5,977,631 | $42,800,000 | 100.00% |
Two Sigma Ventures, LP | 1,806,800 | $12,937,000 | 74.73% |
DCVC Opportunity Fund II GP, LLC | 3,951,141 | $28,290,000 | 31.54% |
MV Management XI, L.L.C. | 1,971,908 | $14,119,000 | 9.80% |
Data Collective IV GP, LLC | 5,941,120 | $42,538,000 | 9.03% |
ArchPoint Investors | 1,267,430 | $9,075,000 | 3.13% |
MIC Capital Management UK LLP | 1,388,889 | $9,944,000 | 1.94% |
HARVARD MANAGEMENT CO INC | 1,509,254 | $10,806,000 | 1.09% |
Samsara BioCapital, LLC | 539,236 | $3,861,000 | 0.97% |
Pinz Capital Management, LP | 142,168 | $1,018,000 | 0.64% |